Additionally, MCL has been demonstrated to counteract tamoxifen resistance in breast cancer (BC) by downregulating the expression of Amidohydrolase 1 (ASAH1), adjusting the ROS/AKT signaling pathway, and activating the NRF2/KEAP1 antioxidant mechanism. The gene discussed is KEAP1; the disease is breast cancer.